Ipamorelin vs CJC-1295
Ipamorelin and CJC-1295 are both studied for their growth hormone (GH) releasing properties, but they operate through different receptor systems. Ipamorelin is a ghrelin mimetic (GHSR agonist), while CJC-1295 is a growth hormone-releasing hormone (GHRH) analog.
Side-by-Side Comparison
| Property | Ipamorelin | CJC-1295 |
|---|---|---|
| Category | Growth hormone secretagogue (ghrelin mimetic) | GHRH analog (modified GRF 1-29) |
| Mechanism of Action | Selective agonist of the growth hormone secretagogue receptor (GHSR/ghrelin receptor); stimulates pulsatile GH release | Binds GHRH receptor on somatotroph cells; amplifies natural GH-releasing hormone signaling |
| Molecular Weight | ~711 Da (5 amino acids) | ~3,367 Da (29 amino acids, with DAC variant ~3,647 Da) |
| Primary Research Focus | GH pulse amplitude, bone mineral density, body composition | Sustained GH elevation, IGF-1 levels, anti-aging research models |
| Receptor Target | GHSR-1a (ghrelin receptor) — highly selective, minimal effect on cortisol, ACTH, or prolactin | GHRH receptor on anterior pituitary somatotrophs |
| Half-Life | ~2 hours | ~30 minutes (mod GRF 1-29); ~8 days (CJC-1295 with DAC) |
| Key Research Citations | Raun et al. (1998), Eur J Endocrinol; Anderson et al. (2001), J Clin Endocrinol Metab | Teichman et al. (2006), J Clin Endocrinol Metab; Ionescu & Bhatt (2004), Horm Res |
Key Differences
- Ipamorelin acts on the ghrelin receptor (GHSR-1a), producing discrete GH pulses. CJC-1295 acts on the GHRH receptor, amplifying the baseline GH-releasing signal.
- Ipamorelin is notably selective — it does not significantly affect cortisol, ACTH, or prolactin levels. CJC-1295 may produce broader hormonal effects.
- CJC-1295 with Drug Affinity Complex (DAC) has a dramatically extended half-life (~8 days) compared to ipamorelin (~2 hours), resulting in sustained rather than pulsatile GH elevation.
- Researchers frequently combine ipamorelin with CJC-1295 (without DAC, i.e., mod GRF 1-29) to leverage both GHRH and ghrelin receptor pathways simultaneously.
Research Summary
Ipamorelin and CJC-1295 target different nodes of the growth hormone axis. Ipamorelin mimics ghrelin to stimulate pulsatile GH release with high selectivity and minimal off-target hormonal effects. CJC-1295 amplifies GHRH signaling, and in its DAC-modified form, provides sustained GH elevation over days rather than hours. The two peptides are often studied together in combination protocols because their distinct mechanisms may produce complementary effects on GH secretion patterns.
Can ipamorelin and CJC-1295 be used together in research?
Yes, ipamorelin and CJC-1295 (mod GRF 1-29) are frequently studied in combination because they target different receptor systems. Ipamorelin activates the ghrelin receptor (GHSR-1a) for pulsatile growth hormone release, while CJC-1295 amplifies GHRH receptor signaling. Their complementary mechanisms may produce synergistic effects on GH secretion patterns.
More Comparisons
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.